EICHORCondition: Hepatocellular Carcinoma · Pancreatic Ductal Adenocarcinoma · Biliary Tract Cancers · Sponsor: AbbVie
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Cohorts 1-8 receive ABBV-400 alone (monotherapy), cohort 9 receives ABBV-400 with a strong CYP3A3 inhibitor (ITZ), and cohort 10 receives ABBV-400 with bevacizumab. All cohorts are followed by a safety follow-up period. Approximately 325 adult participants with hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative breast cancer (TNBC), hormone receptor+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (hormone receptor-positive \[HR+\]/HER2-breast cancer \[BC\]), head and neck squamous-cell-carcinoma (HNSCC), Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer, or advanced solid tumors, will be enrolled in the study in approximately 54 sites worldwide. In cohorts 1-8, participants with the following advanced solid tumor indications: HCC, PDAC, BTC, ESCC, TNBC, HR+/HER2-BC, HNSCC, and PROC/primary peritoneal/fallopian tube cancer will receive intravenous (IV) ABBV-400 monotherapy, in cohor…
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center /ID# 258645 | Duarte, California, United States | — |
| UCSF Medical Center - Mount Zion /ID# 257705 | San Francisco, California, United States | — |
| University of Colorado Cancer Center - Cancer Clinical Trials Office /ID# 255128 | Aurora, Colorado, United States | — |
| Sarah Cannon Research Institute at HealthONE - Denver /ID# 258926 | Denver, Colorado, United States | — |
| Florida Cancer Specialists /ID# 261569 | Sarasota, Florida, United States | — |
| Northwestern University Feinberg School of Medicine /ID# 257378 | Chicago, Illinois, United States | — |
| University of Chicago Medical Center /ID# 258197 | Chicago, Illinois, United States | — |
| START Midwest /ID# 256581 | Grand Rapids, Michigan, United States | — |
| Washington University-School of Medicine /ID# 257379 | St Louis, Missouri, United States | — |
| Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 255132 | New York, New York, United States | — |
| Duke Cancer Center /ID# 255129 | Durham, North Carolina, United States | — |
| Univ Hosp Cleveland /ID# 257706 | Cleveland, Ohio, United States | — |
+ 42 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06084481